The U.S. Food and Drug Administration (FDA) in late March approved the biologic medication certolizumab pegol (Cimzia), a tumor necrosis factor (TNF) inhibitor, to treat a newly defined condition called non-radiographic axial spondyloarthritis (nr-axSpA). Continue reading FDA Approves First Drug for Newly Defined Spinal Condition
Women who have ankylosing spondylitis and men and women who have had the disease longer have an increased risk of developing potentially debilitating symptoms beyond the joints, according to a new study presented at the American College of Rheumatology’s Annual Meeting.
Continue reading Women and Long-Standing Ankylosing Spondylitis Patients at Risk for Other Conditions
For people with ankylosing spondylitis (AS) – a type of inflammatory arthritis that primarily affects the pelvis and spine – a pair of recent studies is shedding light on the possible benefits of a combination treatment with a nonsteroidal anti-inflammatory drug (NSAID) and a tumor necrosis factor (TNF) inhibitor (a type of biologic drug).
In AS, chronic inflammation in the sacroiliac joints (in the pelvis) and in the joints and ligaments along the spine creates pain and stiffness. During the early stages of the disease, joint damage may not be apparent in X-rays. (In these cases, the condition is called nonradiographic axial spondyloarthritis (nr-axSpA). As the disease progresses – and not all cases progress from nr-axSpA to AS – more joint damage occurs as the body grows new bone in an attempt to heal itself, which results in vertebrae fusing together. This reduces mobility and flexibility, and can lead to a hunched posture.
Continue reading Drug Combination May Slow Ankylosing Spondylitis in Some Cases